Most rheumatism drugs can be used safely in SARS-CoV-2 infections. Some even seem to protect against severe cases, but individual drugs were associated with a complicated disease path.
Recent advances in immuno-oncology could open up new treatment options for cardiovascular diseases in the future. A team from Heidelberg (Germany) and Stanford (USA) has found decisive steps in this direction.
Dr. Bianco shares his thoughts on the condition of hospitalised patients, in particular the elderly, and stresses the importance of humanising care in the medical profession.
An international team succeeds on the path to better understand the manifestations of this hereditary disease.
The Roman legions are considered a model of military efficiency. Military medicine was structured, including Greek influences and rituals, to provide care to these exceptional combatants.
An annotated guide to the Guidelines for Home Treatment of SARS-CoV-2 infections - by Dr Carla Bruschelli
Progression of disability in patients with POMS can be predicted by relapse frequency, greater number of relapses with incomplete recovery, amongst others.
PPMS who were originally randomised to ocrelizumab had a lower risk of disability progression than original placebo receivers after 8-years of follow-up.
Ibudilast was associated with reduced retinal atrophy compared with placebo in patients with primary progressive MS (PPMS). This was not the case for SPMS.
Ublituximab was superior to teriflunomide in relapsing MS patients. Annualised relapse rates and MRI parameters demonstrated this.
MS patients treated with ocrelizumab, rituximab, or fingolimod showed a reduced immune response after SARS-CoV-2 mRNA vaccination.
[11C]flumazenil (FMZ) positron emission tomography (PET) demonstrated higher GABA-receptor binding for cognitively preserved (CP) MS patients.
Evobrutinib significantly reduced MRI activity and patient numbers with qualified MS relapses regardless of baseline blood neurofilament light chain levels.
A newly developed dynamic scoring system can be used to support the decision whether or not to switch at an early stage from first- to second-line therapy.
The number of cortical lesions at MS diagnosis accurately discriminates between the presence of absence of cognitive impairment after 20 years.
In a population-based MS cohort, COVID-19 severity and mortality was found to depend on age, comorbidity, and degree of disability.
In both real-world and clinical trial setting, MRI activity is a more sensitive tool to measure disease activity than relapses in secondary progressive MS.
Personality traits that are often seen in patients with a recent MS diagnosis less than 2 years ago are, first and foremost, being highly agreeable, followed by being conscientious, open, and neurotic.
In a comparative analysis of common initial MS therapies among Swedish MS patients, rituximab demonstrated the lowest risk of relapses and MRI lesions.
A high-sensitive technique to detect antibodies to lipids in MS patients was developed. Analysis showd IgM-PC as the most sensitive MS biomarker so far[1].